

Pulsed Electromagnetic Field for Lyme Disease and Chronic Infections

Harry Hong Ph.D. L.Ac.

Current Research on Pulsed Electromagnetic Field

Pulsed Electromagnetic Field (PEMF) has become a popular therapy for many chronic disorders. PEMF accesses biological system through electromagnetic frequencies, which is totally different from conventional chemistry-based methodology. This article is trying to review recent clinical and laboratory research on PEMF and discuss its clinical application and its potential to treat Lyme disease and chronic infections.

PEMF delivers electromagnetic signals to the body stimulating cellular functions. It has been commonly used in the field of orthopedics for the treatment of non-union fractures and failed fusions [1-4]. Laboratory research indicated that PEMF suppresses bone loss [5] through promoting TGF-beta1 and inhibiting IL-6 [6], promoting tissue regeneration [7], enhancing early cell proliferation in osteogenesis [8], and signaling osteogenic differentiation and mineralization [9]. PEMF has also been reported to help osteoarthritis [10] and proposed to be a viable alternative therapy for the disease [11]. Animal research indicated that PEMF had significant efficacy in reducing cartilage damage for osteoarthritis [12], helped healing of the cartilage defect [13], and had positive effect on viability of human chondrocytes in vitro [14].

In addition to its effect on orthopedics, PEMF has also been reported to accelerate wound healing for both animal [15, 16] and human [17], and regenerate nerve tissue [18-20]. It helps to reduce post operational pain [21, 22], chronic musculoskeletal pain [23], pain from carpal tunnel syndrome [24] and diabetic polyneuropathy [19]. It may improve function, pain and fatigue from fibromyalgia [25], help patients with treatment-resistant depression [26], and reduce symptoms from multiple sclerosis [27]. The possible mechanisms for tissue regeneration and pain management has been suggested as provoking a decrease in the production of inflammatory-type cytokines (IL-1 beta and TNF-alpha) and an increase in cytokines of lymphocytic origin (IL-10) [28].

Because of its safe nature, PEMF has a long history of clinical practice. The most controversial figure in PEMF practice is an American named Royal Rife. He believed that each microorganism has its own Mortal Oscillatory Rate (MOR). In early 1930s he published his research and claimed that his Rife Machine, a PEMF device, destroyed microbial with specific electromagnetic frequencies and helped various cancer patients through inactivating the pathogenic virus called BX factor [29]. Although up till now Rife's research has not been reproduced, some recent publications have suggested that Rife's claim may not be entirely impossible. Food industry uses pulsed-electric field to control microbial growth and preserve apple juice [30-32], grape juice [33], wine [34], milk [35] and beer [36]. It suggests that pulsed-electric field inactivate yeast and bacteria including *Lactobacillus diolivorans* [31], *Pediococcus parvulus* [31], *Salmonella enterica* [32], *Bacillus cereus* [35], *Dekkera anomala*, *Dekkera bruxellen-*

sis, *Lactobacillus hilgardii*, *Lactobacillus plantarum* [34], *Kloeckera apiculata*, *Saccharomyces cerevisiae* and *Gluconobacter oxydans* [33]. Although the frequency, intensity and delivery method of the treatment in food industry is different from those used by Rife, the nature of the treatment, pulsed electromagnetic field, remains the same. It is likely to develop therapeutic devices to resolve bacteria, virus, yeast and parasite infections in human body. Most cancer research using PEMF have been done using cancer cell lines. It suggests that PEMF induce apoptosis of melanoma [37], colon carcinoma [38], liver cancer [39] and ovarian carcinoma cell lines [40]. Although the mechanism suggested by above cancer research is different from what Rife proposed, it is still promising to see positive response from cancer cell line research with PEMF. More clinical research is needed to explore this area.

Lyme Disease and Chronic Infections

Lyme disease is the most common tick-borne bacterial infection in temperate areas of the northern hemisphere. The bacteria are called *Borrelia burgdorferi*. Recently the reported incidence of Lyme disease has increased markedly in many countries [41]. Approximately 20,000 cases of Lyme disease are reported annually in the United States alone [42]. Typical Lyme disease may have three stages: 1) early localized infection with erythema migrans (a characteristic skin rash that looks like a bull's-eye), fever, feeling unwell, fatigue, headache, muscle pain and joint pain; 2) early disseminated infection (occurring days to weeks later) with neurological, musculoskeletal, or cardiovascular symptoms; and 3) late disseminated infection with intermittent swelling and pain of one or more joints, neuropathy or encephalopathy [42]. There is evidence that oral antibiotic doxycycline helps *Borrelia* infection [42]. However, some Lyme patients have been reported to be antibiotic resistant [43]. More and more of these patients have been diagnosed as chronic Lyme disease. Patients with chronic Lyme disease are those who have the Lyme symptoms but lack of the initial stage of infection with *Borrelia burgdorferi*, or those who have been previously treated for Lyme disease but had continuing or relapsing nonspecific symptoms such as fatigue, musculoskeletal pain and cognitive complaints. The latter group should be classified as Post-Lyme disease Syndrome (PLS) [44] and antibiotic has been reported to have no impact on this group of patients [45-48].

Typical PLS contains persistent fatigue, musculoskeletal pain and neurocognitive impairment, which are also shown from other commonly diagnosed chronic diseases such as multiple sclerosis (MS), fibromyalgia and chronic fatigue. It suggested that fibromyalgia and chronic fatigue is probably induced by Lyme disease and should be classified into PLS instead [49]. MS is another commonly diagnosed neurological autoimmune condition. Studies suggested that viral infection especially Epstein-Barr infection [50, 51], a common co-infection of Lyme disease, and bacteria infection especially *Borrelia burgdorferi*

infection [52, 53], may play a role in etiology of MS. Laboratory study demonstrated that PLS serum antibody binds cells in the central and peripheral nervous systems and an autoimmune response in PLS has been suggested [54]. It indicated that MS and PLS may have similar etiopathogenesis.

Because of the difficulties to treat chronic Lyme disease and PLS, complementary and alternative medical therapies such as herbal medicine and nutritional supplements have been widely used to treat this condition [55]. Many clinicians who specialize in Lyme disease reported success in treating Lyme disease with alternative therapies such as PEMF [56]. With its effect on tissue regeneration, pain relief, anti-inflammation and anti-microbial, PEMF has potential to become an effective therapy for Lyme disease, MS, fibromyalgia, chronic fatigue, arthritis and many other chronic conditions.

Literature Cited

1. Dallari, D., et al., Effects of pulsed electromagnetic stimulation on patients undergoing hip revision prostheses: a randomized prospective double-blind study. *Bioelectromagnetics*, 2009. 30(6): p. 423-30.
2. Walker, N.A., C.R. Denegar, and J. Preische, Low-intensity pulsed ultrasound and pulsed electromagnetic field in the treatment of tibial fractures: a systematic review. *J Athl Train*, 2007. 42(4): p. 530-5.
3. Foley, K.T., et al., Randomized, prospective, and controlled clinical trial of pulsed electromagnetic field stimulation for cervical fusion. *Spine J*, 2008. 8(3): p. 436-42.
4. Gupta, A.K., K.P. Srivastava, and S. Avasthi, Pulsed electromagnetic stimulation in nonunion of tibial diaphyseal fractures. *Indian J Orthop*, 2009. 43(2): p. 156-60.
5. Prakash, D. and J. Behari, Synergistic role of hydroxyapatite nanoparticles and pulsed electromagnetic field therapy to prevent bone loss in rats following exposure to simulated microgravity. *Int J Nanomedicine*, 2009. 4: p. 133-44.
6. Shen, W.W. and J.H. Zhao, Pulsed electromagnetic fields stimulation affects BMD and local factor production of rats with disuse osteoporosis. *Bioelectromagnetics*, 2010. 31(2): p. 113-9.
7. Sollazzo, V., et al., Effects of pulsed electromagnetic fields on human osteoblastlike cells (MG-63): a pilot study. *Clin Orthop Relat Res*, 2010. 468(8): p. 2260-77.
8. Sun, L.Y., et al., Effect of pulsed electromagnetic field on the proliferation and differentiation potential of human bone marrow mesenchymal stem cells. *Bioelectromagnetics*, 2009. 30(4): p. 251-60.
9. Jansen, J.H., et al., Stimulation of osteogenic differentiation in human osteoprogenitor cells by pulsed electromagnetic fields: an in vitro study. *BMC Musculoskelet Disord*, 2010. 11(1): p. 188.
10. Vavken, P., et al., Effectiveness of pulsed electromagnetic field therapy in the management of osteoarthritis of the knee: a meta-analysis of randomized controlled trials. *J Rehabil Med*, 2009. 41(6): p. 406-11.
11. Ganesan, K., et al., Low frequency pulsed electromagnetic field--a viable alternative therapy for arthritis. *Indian J Exp Biol*, 2009. 47(12): p. 939-48.
12. Fini, M., et al., Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epiphyseal trabecular bone of aged Dunkin Hartley guinea pigs. *Biomed Pharmacother*, 2008. 62(10): p. 709-15.
13. Boopalan, P.R., et al., Pulsed electromagnetic field therapy results in healing of full thickness articular cartilage defect. *Int Orthop*, 2010.
14. Stofa, S., et al., Effects of static magnetic field and pulsed electromagnetic field on viability of human chondrocytes in vitro. *Physiol Res*, 2007. 56 Suppl 1: p. S45-9.
15. Goudarzi, I., et al., Pulsed electromagnetic fields accelerate wound healing in the skin of diabetic rats. *Bioelectromagnetics*, 2010. 31(4): p. 318-23.
16. Matic, M., et al., Influence of different types of electromagnetic fields on skin reparatory processes in experimental animals. *Lasers Med Sci*, 2009. 24(3): p. 321-7.
17. Callaghan, M.J., et al., Pulsed electromagnetic fields accelerate normal and diabetic wound healing by increasing endogenous FGF-2 release. *Plast Reconstr Surg*, 2008. 121(1): p. 130-41.
18. De Pedro, J.A., et al., Pulsed electromagnetic fields induce peripheral nerve regeneration and endplate enzymatic changes. *Bioelectromagnetics*, 2005. 26(1): p. 20-7.
19. Graak, V., et al., Evaluation of the efficacy of pulsed electromagnetic field in the management of patients with diabetic polyneuropathy. *Int J Diabetes Dev Ctries*, 2009. 29(2): p. 56-61.
20. Weintraub, M.I., et al., Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. *Arch Phys Med Rehabil*, 2009. 90(7): p. 1102-9.
21. Zorzi, C., et al., Effects of pulsed electromagnetic fields on patients' recovery after arthroscopic surgery: prospective, randomized and double-blind study. *Knee Surg Sports Traumatol Arthrosc*, 2007. 15(7): p. 830-4.
22. Strauch, B., et al., Evidence-based use of pulsed electromagnetic field therapy in clinical plastic surgery. *Aesthet Surg J*, 2009. 29(2): p. 135-43.
23. Thomas, A.W., et al., A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain. *Pain Res Manag*, 2007. 12(4): p. 249-58.
24. Weintraub, M.I. and S.P. Cole, A randomized controlled trial of the effects of a combination of static and dynamic magnetic fields on carpal tunnel syndrome. *Pain Med*, 2008. 9(5): p. 493-504.
25. Sutbeyaz, S.T., et al., Low-frequency pulsed electromagnetic field therapy in fibromyalgia: a randomized, double-

- blind, sham-controlled clinical study. *Clin J Pain*, 2009. 25(8): p. 722-8.
26. Martiny, K., M. Lunde, and P. Bech, Transcranial low voltage pulsed electromagnetic fields in patients with treatment-resistant depression. *Biol Psychiatry*, 2010. 68(2): p. 163-9.
27. Lappin, M.S., et al., Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. *Altern Ther Health Med*, 2003. 9(4): p. 38-48.
28. Gomez-Ochoa, I., et al., Pulsed electromagnetic fields decrease proinflammatory cytokine secretion (IL-1beta and TNF-alpha) on human fibroblast-like cell culture. *Rheumatol Int*, 2010.
29. Lynes, B. and J. Crane, *The cancer cure that worked! : fifty years of suppression*. 1987, Toronto, Canada: Marcus Books. 167 p.
30. Martinez Viedma, P., et al., Effect of enterocin AS-48 in combination with high-intensity pulsed-electric field treatment against the spoilage bacterium *Lactobacillus diolivorans* in apple juice. *Food Microbiol*, 2009. 26(5): p. 491-6.
31. Martinez Viedma, P., et al., Increased inactivation of exopolysaccharide-producing *Pediococcus parvulus* in apple juice by combined treatment with enterocin AS-48 and high-intensity pulsed electric field. *J Food Prot*, 2010. 73(1): p. 39-43.
32. Martinez Viedma, P., et al., Enhanced bactericidal effect of enterocin AS-48 in combination with high-intensity pulsed-electric field treatment against *Salmonella enterica* in apple juice. *Int J Food Microbiol*, 2008. 128(2): p. 244-9.
33. Marselles-Fontanet, A.R., et al., Optimising the inactivation of grape juice spoilage organisms by pulse electric fields. *Int J Food Microbiol*, 2009. 130(3): p. 159-65.
34. Puertolas, E., et al., Pulsed electric fields inactivation of wine spoilage yeast and bacteria. *Int J Food Microbiol*, 2009. 130(1): p. 49-55.
35. Pina-Perez, M.C., et al., Synergistic effect of pulsed electric fields and CocomanOX 12% on the inactivation kinetics of *Bacillus cereus* in a mixed beverage of liquid whole egg and skim milk. *Int J Food Microbiol*, 2009. 130(3): p. 196-204.
36. Galvagno, M.A., et al., Exploring the use of natural antimicrobial agents and pulsed electric fields to control spoilage bacteria during a beer production process. *Rev Argent Microbiol*, 2007. 39(3): p. 170-6.
37. Ford, W.E., et al., Nanosecond pulsed electric fields stimulate apoptosis without release of pro-apoptotic factors from mitochondria in B16f10 melanoma. *Arch Biochem Biophys*, 2010. 497(1-2): p. 82-9.
38. Hall, E.H., K.H. Schoenbach, and S.J. Beebe, Nanosecond pulsed electric fields induce apoptosis in p53-wildtype and p53-null HCT116 colon carcinoma cells. *Apoptosis*, 2007. 12(9): p. 1721-31.
39. Mi, Y., et al., Effects of steep pulsed electric fields (SPEF) on mitochondrial transmembrane potential of human liver cancer cell. *Conf Proc IEEE Eng Med Biol Soc*, 2007. 2007: p. 5815-8.
40. Yao, C., et al., Experiment and mechanism research of SKOV3 cancer cell apoptosis induced by nanosecond pulsed electric field. *Conf Proc IEEE Eng Med Biol Soc*, 2008. 2008: p. 1044-7.
41. O'Connell, S., Lyme borreliosis: current issues in diagnosis and management. *Curr Opin Infect Dis*, 2010. 23(3): p. 231-5.
42. Bratton, R.L., et al., Diagnosis and treatment of Lyme disease. *Mayo Clin Proc*, 2008. 83(5): p. 566-71.
43. Ghosh, S. and B.T. Huber, Clonal diversification in OspA-specific antibodies from peripheral circulation of a chronic Lyme arthritis patient. *J Immunol Methods*, 2007. 321(1-2): p. 121-34.
44. Marques, A., Chronic Lyme disease: a review. *Infect Dis Clin North Am*, 2008. 22(2): p. 341-60, vii-viii.
45. Mygland, A., et al., EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. *Eur J Neurol*, 2010. 17(1): p. 8-16, e1-4.
46. Pfister, H.W. and T.A. Rupprecht, Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. *Int J Med Microbiol*, 2006. 296 Suppl 40: p. 11-6.
47. Cairns, V. and J. Godwin, Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. *Int J Epidemiol*, 2005. 34(6): p. 1340-5.
48. Krupp, L.B., et al., Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. *Neurology*, 2003. 60(12): p. 1923-30.
49. Bujak, D.I., A. Weinstein, and R.L. Dornbush, Clinical and neurocognitive features of the post Lyme syndrome. *J Rheumatol*, 1996. 23(8): p. 1392-7.
50. Ascherio, A. and K.L. Munger, Epstein-barr virus infection and multiple sclerosis: a review. *J Neuroimmune Pharmacol*, 2010. 5(3): p. 271-7.
51. Munch, M., et al., The implications of Epstein-Barr virus in multiple sclerosis--a review. *Acta Neurol Scand Suppl*, 1997. 169: p. 59-64.
52. Batinac, T., et al., Lyme borreliosis and multiple sclerosis are associated with primary effusion lymphoma. *Med Hypotheses*, 2007. 69(1): p. 117-9.
53. di Bella, P., et al., The presence of anti-Borrelia burgdorferi antibodies in a group of multiple sclerosis patients in eastern Sicily. Preliminary data. *Acta Neurol (Napoli)*, 1993. 15(4): p. 253-7.
54. Chandra, A., et al., Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. *Brain Behav Immun*, 2010. 24(6): p. 1018-24.
55. Vojdani, A., et al., Novel Diagnosis of Lyme Disease: Potential for CAM Intervention. *Evid Based Complement Alternat Med*, 2009. 6(3): p. 283-95.
56. Strasheim, C., *Insights into Lyme Disease Treatment*. 2009, South Lake Tahoe: BioMed Publishing Group.